Accuray has received 510(k) clearance for its new CyberKnife M6 Series from the US Food and Drug Administration (FDA).
Designed for use in stereotactic radiosurgery (SRS) and stereotactic body radiation therapy (SBRT) treatments, the new M6 series features InCise multileaf collimator and includes CyberKnife M6 FIM and FM Systems.
With the integration of InCise, the M6 systems can move around the patient by a robot in 3D to deliver shaped beams to the target in non-isocentric, non-coplanar manner.
University of Pittsburgh School of Medicine radiation oncology, otolaryngology, head and neck surgery professor and vice-chairman Dwight Heron said the InCise collimator is designed to sculpt a single radiation beam matching the exact contour of a tumor, thus minimizing the amount of radiation to the surrounding tissues and reduce the treatment time.
"Now many targets previously unsuited for SRS/SBRT can be treated more quickly and effectively than before," Heron added.
In addition, the CyberKnife M6 systems when used with the CyberKnife’s Synchrony system can track tumors as they move and automatically correct for their movement throughout treatment.
Fox Chase Cancer Centre radiation oncology department vice chairman, radiation physics director Charlie Ma said,"The addition of the MLC, combined with the CyberKnife’s ability to deliver treatment from hundreds of angles while tracking and correcting for motion, will give us the flexibility to deliver the most accurate patient-specific and tailored dose distributions and allows a broader range of patients to benefit from highly efficient and effective treatments."